ArticleFrontiers in nutrition2025
Lipoprotein subclasses and gastrointestinal cancers: novel perspectives and potential associations.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to investigate the associations between serum lipoprotein subclasses and the long-term risk of gastrointestinal (GI) cancers to enhance our understanding of the etiology of GI cancers. Methods: This prospective cohort study included 249,450 participants from the UK Biobank. Cox proportional hazard models were used to assess the association between 17 serum lipoprotein subclasses with the risk of GI cancers. Restricted cubic spline (RCS) analysis was employed to assess the corresponding dose-response relationships. Additionally, Mendelian randomization (MR) analysis was used to evaluate the causal relationships between the lipoproteins and the risk of GI cancers. Results: A total of 4,787 cases of GI cancers were recorded over a median follow-up period of 12.92 years. Our results revealed that the majority of the high-density lipoprotein (HDL) subclasses, such as very large-, large-, and medium-HDL-particles, were positively associated, while several low-density lipoprotein (LDL) subclasses were negatively associated with the risk of overall GI cancer. Additionally, RCS analysis revealed a linear dose-response relationship between elevated levels of most lipoprotein particles and the risk of overall GI cancer development. Additionally, subgroup analysis indicated a significant sex-dependent interaction between lipoprotein particles and the risk of GI cancers. However, MR analysis revealed a different causal relationships between lipoprotein and GI cancers at the genetic level. Conclusion: In this large-scale metabolomics study, we identified several associations between lipoprotein subclasses and the long-term risk of GI cancers. However, further research is needed to fully elucidate their roles in the mechanisms of cancer development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.